This article is more than 5 years old. Information may no longer be current.
Premixed insulin may provide cost-effective option for diabetes
Click Here to Manage Email Alerts
ADA 71st Scientific Sessions
SAN DIEGO — Results from an analysis designed to evaluate the cost-effectiveness of insulin lispro mix 75/25 and insulin lispro mix 50/50 found that the mixed analogues save money in the long-term treatment of type 2 diabetes when compared with long-acting insulin analogues.
Eli Lilly announced the study findings during the President’s Poster Session at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
According to a company press release, the analysis further quantified a recent meta-analysis conducted by the Agency for Healthcare Research and Quality, which assessed the safety and effectiveness of premixed insulin analogues and long-acting insulin analogues, finding that premixed insulin analogues may provide tighter glycemic control vs. long-acting alternatives.
Results demonstrate that insulin lispro mix 75/25 was associated with a life expectancy improvement of 0.07 years and the 50/50 mix with 0.09 years compared with long-acting insulin analogues. The quality-adjusted life expectancy was calculated to be 0.07 years and 0.08 years, respectively. Researchers found that the clinical benefits were accompanied by increases in direct lifetime costs of $1,724 for the 75/25 mix and $1,720 for the 50/50 mix relative to long-acting insulin analogues, yielding incremental cost-effectiveness ratios of $28,580 and $23,150, respectively, per quality-adjusted life-year gained vs. the long-acting alternative.
“We know that 28% of people with type 2 diabetes use insulin to manage their diabetes, and once insulin treatment begins it could be a lifelong part of their disease management,” Dana Hardin, MD, clinical research physician at Eli Lilly, said in the press release. “These study findings are encouraging because, while not all patients are candidates for premixed insulin, those who are may have another viable and cost-effective treatment option.”
To calculate the costs, the base analysis was conducted during a time horizon of 35 years to capture relevant long-term complications and associated costs and assess their affect on life expectancy and quality-adjusted life expectancy. Future cost and clinical outcomes were discounted at 3% annually.
Study limitations included variability in the quality of the reported data on hypoglycemia rates from the studies used for the meta-analysis. Additionally, the meta-analysis represented data from short-term clinical trials, which was extrapolated to make long-term projections, according to information in the press release.
Disclosure: The study was sponsored by Eli Lilly.
 |
Follow EndocrineToday.com on Twitter. |